{"record_type":"pith_number_record","schema_url":"https://pith.science/schemas/pith-number/v1.json","pith_number":"pith:2018:JOEFMQGUGS3XQPC42DFBSRTZMW","short_pith_number":"pith:JOEFMQGU","schema_version":"1.0","canonical_sha256":"4b885640d434b7783c5cd0ca19467965aecd00b76af598a64a7530ba296858ee","source":{"kind":"arxiv","id":"1810.00709","version":1},"attestation_state":"computed","paper":{"title":"TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"stat.ME","authors_text":"Robert L Coleman, Ruitao Lin, Ying Yuan","submitted_at":"2018-10-01T14:06:19Z","abstract_excerpt":"Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immunotherapy make conventional phase II trial designs, which assume a single binary endpoint that is quickly ascertainable, inefficient and dysfunctional. We propose a flexible and efficient time-to-event Bayesian optimal phase II (TOP) design. The TOP design is efficient in that it allows real-time \"go/no-go\" "},"verification_status":{"content_addressed":true,"pith_receipt":true,"author_attested":false,"weak_author_claims":0,"strong_author_claims":0,"externally_anchored":false,"storage_verified":false,"citation_signatures":0,"replication_records":0,"graph_snapshot":true,"references_resolved":false,"formal_links_present":false},"canonical_record":{"source":{"id":"1810.00709","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.ME","submitted_at":"2018-10-01T14:06:19Z","cross_cats_sorted":["stat.AP"],"title_canon_sha256":"5c795a1cfa81da8c5ccdc562ca96d4c8dc7486bc10b90c887877e0e4203b5afa","abstract_canon_sha256":"ab5fddcb4a8c149c18c1f57963ed91b56b4ee202b1838d8d0109f60edae70de8"},"schema_version":"1.0"},"receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T00:04:25.051441Z","signature_b64":"kTQmLJ5ZM+5DlAMJro7M41FjbsIyorpNeUJjCXSmiQ1gOXOibcynrRVC4VBSsh6SINfFPC10c0E41xsPsJF8BA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"4b885640d434b7783c5cd0ca19467965aecd00b76af598a64a7530ba296858ee","last_reissued_at":"2026-05-18T00:04:25.050987Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T00:04:25.050987Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"graph_snapshot":{"paper":{"title":"TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":["stat.AP"],"primary_cat":"stat.ME","authors_text":"Robert L Coleman, Ruitao Lin, Ying Yuan","submitted_at":"2018-10-01T14:06:19Z","abstract_excerpt":"Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer time to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immunotherapy make conventional phase II trial designs, which assume a single binary endpoint that is quickly ascertainable, inefficient and dysfunctional. We propose a flexible and efficient time-to-event Bayesian optimal phase II (TOP) design. The TOP design is efficient in that it allows real-time \"go/no-go\" "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1810.00709","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"aliases":[{"alias_kind":"arxiv","alias_value":"1810.00709","created_at":"2026-05-18T00:04:25.051053+00:00"},{"alias_kind":"arxiv_version","alias_value":"1810.00709v1","created_at":"2026-05-18T00:04:25.051053+00:00"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1810.00709","created_at":"2026-05-18T00:04:25.051053+00:00"},{"alias_kind":"pith_short_12","alias_value":"JOEFMQGUGS3X","created_at":"2026-05-18T12:32:31.084164+00:00"},{"alias_kind":"pith_short_16","alias_value":"JOEFMQGUGS3XQPC4","created_at":"2026-05-18T12:32:31.084164+00:00"},{"alias_kind":"pith_short_8","alias_value":"JOEFMQGU","created_at":"2026-05-18T12:32:31.084164+00:00"}],"events":[],"event_summary":{},"paper_claims":[],"inbound_citations":{"count":0,"internal_anchor_count":0,"sample":[]},"formal_canon":{"evidence_count":0,"sample":[],"anchors":[]},"links":{"html":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW","json":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW.json","graph_json":"https://pith.science/api/pith-number/JOEFMQGUGS3XQPC42DFBSRTZMW/graph.json","events_json":"https://pith.science/api/pith-number/JOEFMQGUGS3XQPC42DFBSRTZMW/events.json","paper":"https://pith.science/paper/JOEFMQGU"},"agent_actions":{"view_html":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW","download_json":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW.json","view_paper":"https://pith.science/paper/JOEFMQGU","resolve_alias":"https://pith.science/api/pith-number/resolve?arxiv=1810.00709&json=true","fetch_graph":"https://pith.science/api/pith-number/JOEFMQGUGS3XQPC42DFBSRTZMW/graph.json","fetch_events":"https://pith.science/api/pith-number/JOEFMQGUGS3XQPC42DFBSRTZMW/events.json","actions":{"anchor_timestamp":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW/action/timestamp_anchor","attest_storage":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW/action/storage_attestation","attest_author":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW/action/author_attestation","sign_citation":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW/action/citation_signature","submit_replication":"https://pith.science/pith/JOEFMQGUGS3XQPC42DFBSRTZMW/action/replication_record"}},"created_at":"2026-05-18T00:04:25.051053+00:00","updated_at":"2026-05-18T00:04:25.051053+00:00"}